Health Condition 1: B079- Viral wart, unspecified
Conditions
Interventions
Intervention1: intralesional vitamin D injection and MMR (measles, mumps, rubella) vaccine: All Group A patients will receive intralesional injection of up to 0.5 mL of reconstituted MMR vaccine into
15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe into the single largest wart. Amount of injection on each wart will depend on the size of each wart. The session wil
Sponsors
sushil kumar singh
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >12 years of either sex 2. Not received any systemic or oral therapy for management of warts in the last 4 weeks. 3. Willing to give consent for inclusion. 4. Willing for 3 weekly follow up.
Exclusion criteria
Exclusion criteria: 1. Patients under any systemic or topical treatment of warts within the last four weeks. 2. Patients with a past history of an allergic response to MMR or any other vaccine or Vitamin D. 3. Immunosuppressed patients • Pregnancy and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical improvement will be graded as a full response, an excellent response, a fair response, a poor response, or no response based on the patients and physicians global evaluation using a visual analogue scale score at each visit, with baseline clinical photographs serving as controls. After each treatment session, the immediate and delayed adverse effects of MMR vaccination.Timepoint: 3 weekly monitoring after each dose and follow up at 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the frequency & location of warts in patients visiting the outpatient department of dermatology at CNMC, Kolkata. 2. To determine the adverse effects associated with intralesional injection of MMR and vitamin D. Timepoint: at three weekly visits | — |
Countries
India
Contacts
Public ContactSUSHIL KUMAR SINGH
calcutta national medical college
Outcome results
None listed